Lipoprotein(a) among normotensive patients and risk of incident hypertension

IF 2.7 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE
Alexander R. Zheutlin, Joshua A. Jacobs, Brian Stamm, Regina Royan
{"title":"Lipoprotein(a) among normotensive patients and risk of incident hypertension","authors":"Alexander R. Zheutlin, Joshua A. Jacobs, Brian Stamm, Regina Royan","doi":"10.1111/jch.14904","DOIUrl":null,"url":null,"abstract":"Lipoprotein(a) has been shown to be disruptive to local endothelial cells, whose integrity is critical to blood pressure (BP) regulation. Cross‐sectional analysis has shown an association between lipoprotein(a) and prevalent hypertension, though it is unclear if lipoprotein(a) increases risk of incident hypertension. To assess this, the authors measured baseline lipoprotein(a) among 5307 normotensive patients (median age 26 years (interquartile range [IQR] 12–50) and used Cox proportional hazard models to generate hazard rations (HR) with 95% confidence intervals (CI; median follow‐up 10‐years). The authors categorized lipoprotein(a) as <15 mg/dL, 15–<30 mg/dL, 30–50 mg/dL, >50 mg/dL, and performed subgroup analysis of adults >50 years at baseline. Incident hypertension was defined as a measured BP ≥140/90 mm Hg or a new ICD‐9/10 code. After adjustment, hypertension for patients with baseline lipoprotein(a) 15–<30 mg/dL, 30–50 mg/dL, and >50 mg/dL was 0.91 (0.72–1.16), 1.05 (0.79–1.38), and 1.02 (0.83–1.26; vs. <15 mg/dL). However, among adults >50 years, lipoprotein(a) >50 mg/dL was associated with increased incident hypertension (1.62 [1.17–2.26]).","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Hypertension","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/jch.14904","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

Lipoprotein(a) has been shown to be disruptive to local endothelial cells, whose integrity is critical to blood pressure (BP) regulation. Cross‐sectional analysis has shown an association between lipoprotein(a) and prevalent hypertension, though it is unclear if lipoprotein(a) increases risk of incident hypertension. To assess this, the authors measured baseline lipoprotein(a) among 5307 normotensive patients (median age 26 years (interquartile range [IQR] 12–50) and used Cox proportional hazard models to generate hazard rations (HR) with 95% confidence intervals (CI; median follow‐up 10‐years). The authors categorized lipoprotein(a) as <15 mg/dL, 15–<30 mg/dL, 30–50 mg/dL, >50 mg/dL, and performed subgroup analysis of adults >50 years at baseline. Incident hypertension was defined as a measured BP ≥140/90 mm Hg or a new ICD‐9/10 code. After adjustment, hypertension for patients with baseline lipoprotein(a) 15–<30 mg/dL, 30–50 mg/dL, and >50 mg/dL was 0.91 (0.72–1.16), 1.05 (0.79–1.38), and 1.02 (0.83–1.26; vs. <15 mg/dL). However, among adults >50 years, lipoprotein(a) >50 mg/dL was associated with increased incident hypertension (1.62 [1.17–2.26]).
正常血压患者的脂蛋白(a)与高血压发病风险
脂蛋白(a)已被证明会破坏局部内皮细胞,而内皮细胞的完整性对血压(BP)调节至关重要。横断面分析表明,脂蛋白(a)与流行性高血压之间存在关联,但目前尚不清楚脂蛋白(a)是否会增加高血压的发病风险。为了评估这一点,作者测量了 5307 名正常血压患者(中位数年龄为 26 岁(四分位数间距 [IQR] 12-50))的基线脂蛋白(a),并使用 Cox 比例危险模型得出危险系数(HR)及 95% 置信区间(CI;中位数随访 10 年)。作者将脂蛋白(a)分为15毫克/分升、15-30毫克/分升、30-50毫克/分升和50毫克/分升,并对基线年龄为50岁的成年人进行了亚组分析。新发高血压的定义是测量血压≥140/90 mm Hg 或有新的 ICD-9/10 编码。经过调整后,基线脂蛋白(a)为 15<30 mg/dL、30-50 mg/dL 和 >50 mg/dL 的高血压患者的血压分别为 0.91(0.72-1.16)、1.05(0.79-1.38)和 1.02(0.83-1.26;对比<15 mg/dL)。然而,在 50 岁的成年人中,脂蛋白(a)50 毫克/分升与高血压发病率增加有关(1.62 [1.17-2.26])。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Clinical Hypertension
Journal of Clinical Hypertension PERIPHERAL VASCULAR DISEASE-
CiteScore
5.80
自引率
7.10%
发文量
191
审稿时长
4-8 weeks
期刊介绍: The Journal of Clinical Hypertension is a peer-reviewed, monthly publication that serves internists, cardiologists, nephrologists, endocrinologists, hypertension specialists, primary care practitioners, pharmacists and all professionals interested in hypertension by providing objective, up-to-date information and practical recommendations on the full range of clinical aspects of hypertension. Commentaries and columns by experts in the field provide further insights into our original research articles as well as on major articles published elsewhere. Major guidelines for the management of hypertension are also an important feature of the Journal. Through its partnership with the World Hypertension League, JCH will include a new focus on hypertension and public health, including major policy issues, that features research and reviews related to disease characteristics and management at the population level.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信